NY-AMERICAN-EXPRESS
21.3.2022 14:02:44 CET | Business Wire | Press release
American Express (NYSE:AXP) released the American Express Travel: 2022 Global Travel Trends Report 1 today, which shows people are looking forward to more trips than last year and planning to spend more or the same on travel in 2022 compared to a typical pre-pandemic year. The report, based on data from the United States, Australia, Canada, Mexico, Japan, India and the United Kingdom, reveals consumers are traveling to see the people and places they love, celebrate important life events, embark on wish list trips, experience in-person events, and to seek greater wellness and self-care. In Q4 2021, global Card Member bookings made through American Express Travel were up 24% compared to 2019 and have continued to strengthen in 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220321005163/en/
“The pandemic has made all of us, including travelers, assess what is truly important,” said Audrey Hendley, President of American Express Travel. “The Global Travel Trends Report shows that tourists are making up for lost time and being thoughtful about who they travel with, the places they visit, the brands they support, and how they spend their money as the travel industry moves forward.”
Top insights from the American Express Travel: 2022 Global Travel Trends Report1 include:
- The world is ready to travel: 74% of respondents agree they are willing to book a trip for 2022 even if they might have to cancel or modify it later1 . This is up from 56% last year2 .
- Spending on travel is outpacing pre-pandemic levels : 86% of consumers expect to spend more or the same on travel in 2022 compared to a typical pre-pandemic year1 .
- Tourists want to travel more frequently: 62% of respondents plan on taking 2-4 trips in 2022 and 76% of respondents agree they plan to travel more with family in 2022 than they did in 2021.
- Tourists are seeking out brands that prioritize supporting local communities: 81% of respondents want to visit destinations where they can immerse themselves in the local culture and want the money they spend while traveling to go back to the local community.
- Dream destinations are becoming a reality: 55% of respondents want to book a once-in-a-lifetime vacation this year; especially true for Millennials (67%) and Gen Z (65%).
- As entertainment returns so do trips tied to in-person events: 56% of respondents stated they held off on traveling for major entertainment events last year but have plans to return to these types of events this year.
As travel momentum continues to grow, American Express Travel offers exclusive access and value, unique programs and benefits, and access to best-in-class travel expertise through American Express Travel Consultants who back Card Members with any type of trip.
The full American Express Travel: 2022 Global Travel Trends Report can be found here .
1 Survey Methodology: This Amex Trendex online poll was conducted by Morning Consult between February 3- 11th, 2022 among a national sample of 2,000 US and 1,000 travelers in Australia, Canada, India, Japan, Mexico, the UK, and the US who have a household income of at least $70K and defined as adults who typically travel by air at least once a year. Results from each market’s survey have a margin of error of plus or minus 3 percentage points.
2 Survey Methodology: This Amex Trendex online poll was conducted by Morning Consult between January 15-24, 2021 among a national sample of 1,000 travelers in Australia, Canada, India, Japan, Mexico and the U.K., and 2,000 in the U.S. $70k+ USD household income (HHI) equivalent in Australia, Canada, Japan, the U.K. and the U.S., $50k+ USD equivalent HHI in Mexico, and $20k+ USD equivalent household income in India. Travelers defined as adults who traveled by air at least once in 2019. Results have a margin of error of plus or minus 2 percentage points in the U.S.; plus or minus 3 percentage points in the other countries.
ABOUT AMERICAN EXPRESS
American Express is a globally integrated payments company, providing customers with access to products, insights and experiences that enrich lives and build business success. Learn more at americanexpress.com and connect with us on facebook.com/americanexpress , instagram.com/americanexpress , linkedin.com/company/american-express , twitter.com/americanexpress , and youtube.com/americanexpress .
Key links to products, services and corporate responsibility information: personal cards , business cards , travel services , gift cards , prepaid cards , merchant services , Accertify , Kabbage , Resy , corporate card , business travel , diversity and inclusion , corporate responsibility and Environmental, Social, and Governance reports .
Location: Global
View source version on businesswire.com: https://www.businesswire.com/news/home/20220321005163/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom